[go: up one dir, main page]

WO2016169041A1 - Substance de renforcement de tissus biologiques - Google Patents

Substance de renforcement de tissus biologiques Download PDF

Info

Publication number
WO2016169041A1
WO2016169041A1 PCT/CN2015/077342 CN2015077342W WO2016169041A1 WO 2016169041 A1 WO2016169041 A1 WO 2016169041A1 CN 2015077342 W CN2015077342 W CN 2015077342W WO 2016169041 A1 WO2016169041 A1 WO 2016169041A1
Authority
WO
WIPO (PCT)
Prior art keywords
cellulose
biological tissue
reinforcing material
fiber structure
structure made
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/077342
Other languages
English (en)
Inventor
Chiaki Tanaka
Yoshinari Yui
Keishi Kiminami
Shojiro Matsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gunze Medical Devices (shenzhen) Ltd
Gunze Ltd
Original Assignee
Gunze Medical Devices (shenzhen) Ltd
Gunze Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gunze Medical Devices (shenzhen) Ltd, Gunze Ltd filed Critical Gunze Medical Devices (shenzhen) Ltd
Priority to CN201580078714.7A priority Critical patent/CN107530212B/zh
Priority to JP2017533344A priority patent/JP6470840B2/ja
Priority to PCT/CN2015/077342 priority patent/WO2016169041A1/fr
Publication of WO2016169041A1 publication Critical patent/WO2016169041A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds

Definitions

  • the present invention relates to a biological tissue-reinforcing material capable of more reliably reinforcing weakened tissue while preventing air leakage or fluid leakage without using fibrin glue, which is a blood product.
  • the most fundamental issue in the field of surgery is to repair a damaged or weakened organ or tissue. For example, bleeding of a damaged organ is still treated by stopping bleeding and suturing the wound, which is the most commonly used surgical procedure to stop bleeding even now. Furthermore, another important issue in the surgical treatment is to prevent fluid leakage or air leakage from weakened or damaged tissue. Particularly in the field of chest surgery, it is important to prevent air leakage due to pneumothorax or after resection of lung cancer. In particular, pneumothorax is a disease that is difficult to treat because the recurrence rate is increased without appropriate treatment.
  • Pneumothorax often occurs due to air leakage into a thoracic cavity from a stump or suture site of the lung after resection, a site of the lung after partial resection to remove lung cancer, or a damaged site of lung tissue due to injury; or air leakage into a thoracic cavity from a tear of cysts (referred to bullae) which are transformed from some alveoli.
  • Such leakage has been treated by pleurodesis in which lung tissue is allowed to adhere to pleura with drugs or by artificial chemical burns.
  • Pleurodesis can prevent recurrence of pneumothorax to some extent.
  • the recurrence rate is increased. I f further surgery is needed, adhesion between lung tissue and parietal pleura needs to be removed, which prolongs a surgical time or causes bleeding during removal of the adhesion. Therefore, new treatment alternative to pleurodesis has been investigated.
  • pancreatic juice dissolves granulation tissue that is responsible for wound healing, and prevents the growth of the tissue, leading to difficulty in regeneration of pancreatic tissue. Furthermore, it is concerned that leakage of pancreatic juice digests blood vessels to possibly cause postoperative hemorrhage, which is a life-threatening complication.
  • Non-Patent Literatures 1 to 4 suggest that this method more reduces the recurrence rate of pneumothorax than usual pleurodesis.
  • Non-Patent Literature 5 suggests that such a method is also used to prevent bleeding after liver resection in the field of digestive surgery.
  • fibrin glue and a fiber structure made of a bioabsorbable polymer in combination are remarkably effective to reinforce weakened tissue.
  • air leakage or fluid leakage may occur even at a reinforced area, which may give rise to the need of further surgery. The incidence of such a case is not high, but leakage may become a risk factor to cause severe symptoms. Therefore, a reliable method of reinforcement has been needed.
  • fibrin glue which is a blood product, may lead to unknown viral infection.
  • Non-Patent Literature 1 J. Pediatric Surg, 42, 1225-1230 (2007)
  • Non-Patent Literature 2 Interact. Cardiovasc. Thorac. Surg, 6, 12-15 (2007)
  • Non-Patent Literature 3 The Journal of the Japanese
  • Non-Patent Literature 4 The Journal of the Japanese
  • Non-Patent Literature 5 The Japanese Journal of Clinical and Experimental Medicine, 84, 148 (2007)
  • the present invention is a biological tissue-reinforcing material comprising a laminated structure, the laminated structure comprising: a fiber structure made of a bioabsorbable polymer; and a fiber structure made of etherified cellulose that is produced through etherification of hydroxy groups of cellulose.
  • the present inventors have researched the cause of air leakage or fluid leakage from a reinforced area of biological tissue reinforced using fibrin glue and a fiber structure made of a bioabsorbable polymer in combination, and found that the cause of the leakage is in an adhesion area with fibrin glue.
  • Fibrin glue which gels in a short time, is very useful as biological glue.
  • fibrin glue in the form of a gel is relatively hard, cohesive failure or interfacial peeling is likely to occur due to impact.
  • cohesive failure or interfacial peeling presumably occurs by a very high pressure applied to lung tissue by coughing or sneezing. Gelled fibrin glue once separated cannot adhere again because of its less adhesion. Air leakage or fluid leakage presumably occurs at such a separation area.
  • etherified cellulose produced through etherification of hydroxy groups of cellulose (hereinafter, also referred to as "etherified cellulose” ) instead of fibrin glue allows more reliable reinforcement of weakened tissue, and gives a biological tissue-reinforcing material that causes no air leakage or fluid leakage. As a result, the present invention has been completed.
  • Etherified cellulose is a compound proven to be highly safe, and gels in a short time like fibrin glue to act as glue to attach a fiber structure made of a bioabsorbable polymer to biological tissue. Further, since gelled etherified cellulose has a certain level of adhesive force, even if cohesive failure or interfacial peeling occurs due to high pressure, the etherified cellulose can adhere again to prevent air leakage or fluid leakage. Further, since etherified cellulose can be processed into fiber, a laminated structure preliminary made by laminating a fiber structure made of such etherified cellulose on a fiber structure made of a bioabsorbable polymer can provide a biological tissue-reinforcing material remarkably easy to use.
  • the biological tissue-reinforcing material of the present invention has a laminated structure that includes a fiber structure made of a bioabsorbable polymer and a fiber structure made of etherified cellulose.
  • the fiber structure made of a bioabsorbable polymer is designed to show a tissue reinforcement effect, an air leakage prevention effect, and a fluid leakage prevention effect when it is attached to a damaged or weakened organ.
  • the fiber structure made of etherified cellulose absorbs moisture to gel, and acts as glue to attach the fiber structure made of a bioabsorbable polymer to biological tissue.
  • bioabsorbable polymers include, but are not particularly limited to, synthetic absorbable polymers such as a ⁇ -hydroxy acid polymer (e.g. polyglycolide, polylactide (D, L, DL isomer) , glycolide-lactide (D, L, DL isomer) copolymers, glycolide- ⁇ -caprolactone copolymers, lactide (D, L, DL isomer) - ⁇ -caprolactone copolymers, poly (p-dioxanone) , and glycolide-lactide (D, L, DL isomer) - ⁇ -caprolactone copolymers) ; and natural absorbable polymers such as collagen, gelatin, chitosan, or chitin.
  • synthetic absorbable polymers such as a ⁇ -hydroxy acid polymer (e.g. polyglycolide, polylactide (D, L, DL isomer) , glycolide-lactide (D, L
  • a natural absorbable polymer may be used together therewith.
  • a ⁇ -hydroxy acid polymer which is a homopolymer or copolymer of at least one monomer selected from the group consisting of glycolide, lactide, ⁇ -caprolactone, dioxanone, and trimethylene carbonate is preferred because of its high strength.
  • a ⁇ -hydroxy acid polymer which is a homopolymer or copolymer of a monomer containing glycolide is more preferred because the polymer shows appropriate decomposition behavior.
  • the preferable lower limit of a weight average molecular weight of the polyglycolide is 30000, and the preferable upper limit thereof is 1000000.
  • Polyglycolide having the weight average molecular weight of less than 30000 is poor in strength and may not impart a sufficient tissue reinforcement effect.
  • Polyglycolide having the weight average molecular weight of more than 1000000 slowly decomposes in the body and therefore may lead to a foreign-body reaction.
  • the more preferable lower limit of the weight average molecular weight of the polyglycolide is 50000, and the more preferable upper limit thereof is 300000.
  • the fiber structure made of the bioabsorbable polymer may be in any form, and may be in the form of a non-woven fabric, a knitted fabric, a woven fabric, gauze, or yarn. In addition, these forms may be combined one another. In particular, a non-woven fabric is preferred.
  • the weight per unit area of the non-woven fabric is not particularly limited, and the preferable lower limit is 5 g/m 2 , and the preferable upper limit is 300 g/m 2 .
  • a non-woven fabric having a weight per unit area of less than 5 g/m 2 has strength not enough for a biological tissue-reinforcing material, and may not reinforce weakened tissue.
  • a non-woven fabric having a weight per unit area of more than 300 g/m 2 may poorly adhere to tissue.
  • the more preferable lower limit of the weight per unit area of the non-woven fabric is 10 g/m 2 , and the more preferable upper limit thereof is 100 g/m 2 .
  • the non-woven fabric may be produced by any method, and examples of the method include conventionally known methods such as electro spinning deposition, melt blowing, needle punching, spun bonding, flash spinning, hydroentanglement, air laying, thermal bonding, resin bonding, or wet processing.
  • the fiber structure made of the bioabsorbable polymer may be subj ected to hydrophilization.
  • the fiber structure subj ected to hydrophilization rapidly absorbs moisture such as normal saline in contact with the structure, and is therefore easily used.
  • hydrophilization examples include, but are not particularly limited to, plasma treatment, glow discharge treatment, corona discharge treatment, ozone treatment, surface graft treatment, ultraviolet irradiation treatment, and the like.
  • plasma treatment is preferred because it remarkably increases the water absorption rate without changing the outward appearance of the non-woven fabric.
  • the thickness of the fiber structure made of the bioabsorbable polymer is not particularly limited, and the preferable lower limit is 5 ⁇ m, and the preferable upper limit is 1.0 mm.
  • a fiber structure made of the bioabsorbable polymer having a thickness of less than 5 ⁇ m is poor in strength and may not impart a sufficient tissue reinforcement effect.
  • a fiber structure made of the bioabsorbable polymer having a thickness of more than 1.0 mm may not sufficiently adhere to and fix tissue.
  • the more preferable lower limit of the thickness of the fiber structure made of the bioabsorbable polymer is 10 ⁇ m, and the more preferable upper limit thereof is 0.5 mm.
  • the etherified cellulose is produced through etherification of hydroxy groups of cellulose.
  • hydroxyalkylated cellulose represented by the formula (1) such as hydroxyethylated cellulose in which hydroxy groups of cellulose are replaced with hydroxyethyl groups, and hydroxypropylated cellulose in which hydroxy groups of cellulose are replaced with hydroxypropyl groups.
  • hydroxyethylated cellulose which is proven to be highly safe, is preferred.
  • n represents an integer
  • R represents hydrogen or-R’ OH in which R’ represents an alkylene group.
  • the molar ratio of a diethylene glycol group to an ethylene glycol group is preferably 0.1 to 1.0, and the molar ratio of a triethylene glycol group to an ethylene glycol group (triethylene glycol group/ethylene glycol group) is preferably 0.1 to 0.5.
  • the etherified cellulose having molar ratios within such ranges imparts excellent initial adhesive force when the fiber structure made of the bioabsorbable polymer adheres to biological tissue through the fiber structure made of the etherified cellulose, and the high adhesive force is maintained even after adhesion. Even if cohesive failure or interfacial peeling occurs due to high pressure, the etherified cellulose can adhere again to prevent air leakage or fluid leakage.
  • the numbers of moles of ethylene glycol groups, diethylene glycol groups, and triethylene glycol groups can be measured, for example, by NMR or thermal decomposition GC-MS.
  • the preferable lower limit of the average number of molecules (Molar Substitution, MS) of alkylene oxides bonded to one anhydroglucose unit is 1.0, and the preferable upper limit thereof is 4.0.
  • the etherified cellulose having a MS within such a range can gel in a short time with high gel strength, and closely adhere to and fix tissue. If the MS is less than 1.0, gelled hydroxyethylated cellulose tends to be less viscous. If the MS is more than 4.0, gelation tends to need a long time.
  • the more preferable lower limit of the MS is 1.3, and the more preferable upper limit thereof is 3.0.
  • the preferable lower limit of the average degree of substitution (DS) of alkylene oxides to hydroxyl groups at positions 2, 3, and 6 of an anhydroglucose unit is 0.2, and the preferable upper limit thereof is 2.5.
  • the etherified cellulose having a DS within such a range can gel in a short time with high gel strength, and closely adhere to and fix tissue. Furthermore, the strength due to the fiber structure is likely to be imparted, and fibers are likely to retain moisture therein. If the DS is less than 0.2, gelation may need a long time. If the DS is more than 2.5, the strength due to the fiber structure in a wet condition may reduce.
  • the more preferable lower limit of the DS is 0.3, and the more preferable upper limit thereof is 1.5.
  • the MS and DS can be calculated from the measurement of NMR spectrum of an aqueous solution of hydroxyethylated cellulose, and the quantification of the intensities of signals belonging to carbon atoms of an anhydroglucose ring and carbon atoms of a substituent group in the spectrum (see for example JP-H6-41926 B) .
  • 0.2 g of a sample, 30 mg of an enzyme (cellulase) , and an internal standard material are dissolved in 3 ml of heavy water.
  • the resulting solution is subj ected to ultrasonication for 4 hours, and its NMR spectrum is determined using an NMR measuring device (e. g. JNM-ECX400P produced by JEOL) under the conditions of the number of scanning of 700, pulse width of 45°, and observed frequency of 31500 Hz.
  • an NMR measuring device e. g. JNM-ECX400P produced by JEOL
  • the hydroxyethylated cellulose can be produced, for example, by the reaction of an ethylene oxide with alkali cellulose produced by treating cellulose with an aqueous solution of an alkali.
  • alkali cellulose is produced from a fiber structure made of cellulose as a raw material by treating the fiber structure with an aqueous solution of an alkali such as sodium hydroxide. Then, to the resulting alkali cellulose are added a certain amount of an ethylene oxide and a reaction solvent, and a reaction is performed.
  • an alkali such as sodium hydroxide
  • the preferable lower limit of a water absorption rate of the fiber structure made of the etherified cellulose is 200%, and the preferable upper limit thereof is 1000%.
  • the fiber structure made of the etherified cellulose having the water absorption rate within such a range can gel in a short time with high gel strength, and closely adhere to and fix tissue. If the water absorption rate is lower than 200%, gelation may need a long time. If the water absorption rate is higher than 1000%, gel strength tends to reduce.
  • the more preferable lower limit of the water absorption rate is 400%, and the more preferable upper limit thereof is 800%.
  • the water absorption rate herein can be measured by the following method.
  • the initial weight of a sample is measured, and it is placed in a petri dish. Distilled water is slowly added dropwise to the sample.
  • the weight of the sample containing absorbed distilled water to the maximum is determined as a maximum water absorption weight.
  • the water absorption rate can be determined from the following equation using the resulting initial weight and the maximum water absorption weight.
  • Water absorption rate (%) (maximum water absorption weight -initial weight) /initial weight ⁇ 100
  • the preferable lower limit of a moisture absorption rate of the fiber structure made of the etherified cellulose is 7%, and the preferable upper limit thereof is 50%.
  • the fiber structure made of the etherified cellulose having the moisture absorption rate within such a range can gel in a short time with high gel strength, and closely adhere to and fix tissue. I f the moisture absorption rate is lower than 7%, gelation may need a long time. If the moisture absorption rate is higher than 50%, the gel strength tends to reduce.
  • the more preferable lower limit of the moisture absorption rate is 10%, and the more preferable upper limit thereof is 35%.
  • the moisture absorption rate used herein can be measured by the following method.
  • a sample is heated at 105°C for 2 hours.
  • the weight of the resulting sample is determined as an absolute dry weight.
  • the absolute dry sample is allowed to stand in an atmosphere at 20°C and 65%Rh for 7 hours to control the moisture content of the sample.
  • the weight of the sample is determined as a weight after moisture control.
  • a moisture absorption rate can be calculated from the following equation using the resulting absolute dry weight and the weight after moisture control.
  • Moisture absorption rate (%) (weight after moisture control -absolute dry weight) /absolute dry weight ⁇ 100
  • the fiber structure made of the etherified cellulose may be in any form, and may be in the form of a non-woven fabric, a knitted fabric, a woven fabric, gauze, or yarn.
  • the fiber structures having such forms may be combined one another.
  • a non-woven fabric is preferred.
  • the weight per unit area of the non-woven fabric is not particularly limited, and the preferable lower limit is 20 g/m 2 , and the preferable upper limit is 700 g/m 2 . If the non-woven fabric has a weight per unit area of less than 20 g/m 2 , the biological tissue-reinforcing material cannot be attached to biological tissue with sufficient adhesive force. If the non-woven fabric has the weight per unit area of more than 700 g/m 2 , gelation of etherified cellulose may need a long time. The more preferable lower limit of the weight per unit area of the non-woven fabric is 50 g/m 2 , and the more preferable upper limit thereof is 500 g/m 2 .
  • the thickness of the fiber structure made of the etherified cellulose is not particularly limited, and the preferable lower limit is 50 ⁇ m, and the preferable upper limit is 10 mm.
  • a fiber structure made of the etherified cellulose having a thickness of less than 50 ⁇ m may not allow adhesion of the biological tissue-reinforcing material to biological tissue with sufficient adhesive force.
  • a fiber structure made of the etherified cellulose having a thickness of more than 10 mm is less likely to absorb water, has an impaired texture, and may be poorly operatable.
  • the more preferable lower limit of the thickness of the fiber structure made of the etherified cellulose is 50 ⁇ m, and the more preferable upper limit thereof is 5 mm.
  • the fiber structure made of the bioabsorbable polymer and the fiber structure made of the etherified cellulose are preferably integrally combined.
  • a structure integrally combined shows more enhanced easiness of use.
  • the method of integrally combining may be any method, and examples of the method include needle punching, hydroentanglement, air entanglement, knitting, and weaving or spray spinning (melt blowing, electrospinning) .
  • integrally combined means a state where two fiber structures laminated to each other can be treated as one structure, and are not easily separated.
  • the biological tissue-reinforcing material of the present invention is used to stop bleeding from a damaged or weakened organ or tissue, or to prevent air leakage or fluid leakage in the field of surgery.
  • the biological tissue-reinforcing material is favorably used to prevent air leakage due to pneumothorax or after resection of lung cancer in the field of chest surgery.
  • the biological tissue-reinforcing material of the present invention can be easily attached to an affected area just by placing, at the affected area, the material preliminary immersed into normal saline. Further, the biological tissue-reinforcing material absorbs blood or fluid from an affected area to show adhesive force.
  • Fig. 1 is a view schematically illustrating pressure test equipment used in the pressure test performed in examples.
  • the present invention can provide a biological tissue-reinforcing material capable of more reliably reinforcing weakened tissue while preventing air leakage or fluid leakage without using fibrin glue, which is a blood product.
  • a 280- ⁇ m-thick single knit made of No. 80 count cellulose yarn as a raw material was bleached by hydrogen peroxide bleaching.
  • a 150- ⁇ m-thick non-woven fabric (NEOVEIL Type NV-M015G produced by GUNZE LIMITED) made of polyglycolide was prepared as a fiber structure made of a bioabsorbable polymer.
  • a biological tissue-reinforcing material was obtained in such a way that a combination of two fiber structures made of hydroxyethylated cellulose/anon-woven fabric made of polyglycolide/one fiber structure made of hydroxyethylated cellulose were laminated in the stated order, and they were integrally combined by needle punching.
  • the resulting biological tissue-reinforcing material was cut into a 9-mm-diameter circular shape to give a test sample for measurement.
  • An about 130- ⁇ m-thick collagen film (produced by Nippi. Inc. ) was cut into a 24-mm-diameter circular shape, and the cut film was washed with 70%ethanol, and liquid was wiped off.
  • the cut film was set in a filter holder 2 (Swinnex (registered trademark) 25 produced by Merck Millipore. )
  • a 3-mm-diameter hole was formed in the center of the collagen film that was set in the filter holder 2 using a punch.
  • a 20-ml syringe 3 (Terumo Syringe SS-20ESZ produced by TERUMO CORPORATION) and a pressure gauge 5 (digital manometer FUSO-8230 produced by FUSORIKA Co., Ltd. ) were placed at the downstream of the filter holder through a three way cock 4. In this manner, pressure test equipment was fabricated.
  • Purified water was added dropwise to the surface on the side of the combination of two fiber structures made of hydroxyethylated cellulose of the test sample.
  • the resulting test sample was placed at the center of the collagen film that was set in the filter holder such that the surface on the side of the combination of two fiber structures was in contact with the collagen film.
  • air was delivered to the test sample through a syringe.
  • the maximum pressure that does not cause peeling of the test sample was measured using a pressure gauge, and the pressure resistance (initial pressure resistance) was evaluated.
  • the initial pressure resistance air was delivered through a syringe every five minutes five times and at each time, the maximum pressure of the air for peeling the test sample was measured using a pressure gauge, and the repeatability of the pressure resistance was evaluated.
  • a biological tissue-reinforcing material made of was obtained in the same manner as in Example 1, except that a fiber structure made of hydroxyethylated cellulose was prepared from a 200- ⁇ m-thick single knit made of No. 160 count cellulose yarn as a raw material, and a combination of three fiber structures made of hydroxyethylated cellulose/a non-woven fabric made of polyglycolide/a combination of two fiber structures made of hydroxyethylated cellulose were laminated in the stated order.
  • the biological tissue-reinforcing material was subj ected to a pressure test. In the pressure test, the resulting test sample was placed at the center of the collagen film that was set in the filter holder such that the surface on the side of the combination of the three fiber structures made of hydroxyethylated cellulose was in contact with the collagen film.
  • Table 1 shows the results of the pressure test.
  • a 150- ⁇ m-thick non-woven fabric made of polyglycolide (NEOVEIL Type NV-M015G produced by GUNZE LIMITED) was cut into a 9-mm-diameter circular shape.
  • a collagen film was set in the filter holder of the pressure test equipment prepared in Example 1. Then, 20 ⁇ L of liquid A of fibrin glue (Beriplast P produced by CSL Behring K.K.) was added dropwise to the center of the collagen film so as to avoid hole of the collagen film and spread in an approximately 9-mm-diameter shape. Next, the non-woven fabric cut into a 9-mm-diameter circular shape was placed on the spread liquid A, and was impregnated with the liquid A. Then, 40 ⁇ L of the liquid A was added dropwise to the non-woven fabric, and the non-woven fabric was sufficiently impregnated with the liquid A. Then, 40 ⁇ L of liquid B was added dropwise to the non-woven fabric. After 15 minutes have passed from the end of dropping of the liquid B, air was delivered through a syringe, and the maximum pressure that does not cause peeling the test sample was measured using a pressure gauge, and the pressure resistance (initial pressure resistance) was evaluated.
  • fibrin glue produced by
  • a biological tissue-reinforcing material was obtained in the same manner as in Example 1, except that a fiber structure made of oxidized cellulose (SURGICEL produced by Johnson &Johnson K.K.) was used instead of the fiber structure made of hydroxyethylated cellulose.
  • the biological tissue-reinforcing material was subj ected to a pressure test.
  • Table 1 shows the results of the pressure test.
  • Table 1 shows that in the case of using fibrin glue and a fiber structure made of a bioabsorbable polymer in combination, the initial pressure resistance was relatively high, as high as 34.7 mmHg, but remarkable reduction in pressure resistance was observed in the test sample once separated by pressure (from the second measurement) . The pressure resistance did not return to the original level.
  • the initial pressure resistances were high (59.3 mmHg and 52.1 mmHg) .
  • little reduction in pressure resistance was observed in the test samples once separated by pressure (from the second measurement) . It is considered that this is because the test samples adhere again during a 5-minute interval.
  • Comparative Example 2 a case of using a fiber structure made of oxidized cellulose, which was known as an absorbable hemostat, was tested. As a result, the initial pressure resistance was as low as 20.7 mmHg, and reduction in pressure resistance was observed in each measurement from the second measurement.
  • the present invention can provide a biological tissue-reinforcing material capable of more reliably reinforcing weakened tissue while preventing air leakage and fluid leakage without using fibrin glue, which is a blood product.
  • the biological tissue-reinforcing material of the present invention can also be used for a dura mater, an oral mucosa, adhesion preventive materials, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Materials For Medical Uses (AREA)
  • Laminated Bodies (AREA)
  • Nonwoven Fabrics (AREA)

Abstract

La présente invention concerne une substance de renforcement de tissus biologiques permettant de renforcer des tissus affaiblis de manière plus fiable tout en empêchant une fuite d'air et une fuite de fluide sans utiliser de colle à la fibrine, qui est un produit sanguin． La présente invention concerne une substance de renforcement de tissus biologiques comprenant une structure stratifiée, ladite structure stratifiée comprenant : une structure fibreuse constituée d'un polymère bioabsorbable; et une structure fibreuse constituée de cellulose éthérifiée qui est produite par éthérification de groupes hydroxyle d'une cellulose.
PCT/CN2015/077342 2015-04-24 2015-04-24 Substance de renforcement de tissus biologiques Ceased WO2016169041A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201580078714.7A CN107530212B (zh) 2015-04-24 2015-04-24 生物组织加固材料
JP2017533344A JP6470840B2 (ja) 2015-04-24 2015-04-24 生体組織補強材料
PCT/CN2015/077342 WO2016169041A1 (fr) 2015-04-24 2015-04-24 Substance de renforcement de tissus biologiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/077342 WO2016169041A1 (fr) 2015-04-24 2015-04-24 Substance de renforcement de tissus biologiques

Publications (1)

Publication Number Publication Date
WO2016169041A1 true WO2016169041A1 (fr) 2016-10-27

Family

ID=57144573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/077342 Ceased WO2016169041A1 (fr) 2015-04-24 2015-04-24 Substance de renforcement de tissus biologiques

Country Status (3)

Country Link
JP (1) JP6470840B2 (fr)
CN (1) CN107530212B (fr)
WO (1) WO2016169041A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071587A1 (fr) * 2017-10-13 2019-04-18 Gunze Limited Kit de matériau de renforcement de tissu biologique et matériau de renforcement de tissu biologique
CN109937055A (zh) * 2016-11-07 2019-06-25 郡是株式会社 生物组织增强材料和人工硬脑膜
JP2019528806A (ja) * 2016-11-07 2019-10-17 グンゼ株式会社 生体組織補強材料

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1799649A (zh) * 2005-12-09 2006-07-12 清华大学 一种血液相容性生物材料及其制备方法
CN101137402A (zh) * 2004-10-20 2008-03-05 伊西康公司 供医疗装置用的加固可吸收多层织物及其制备方法
CN102600013A (zh) * 2012-03-21 2012-07-25 苏州博创同康生物工程有限公司 一种医用植绒止血材料及其制备和应用
CN104207879A (zh) * 2013-05-31 2014-12-17 天津法莫西医药科技有限公司 具有羧甲基纤维素钠/聚乳酸海绵保护层的医用敷料

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500777B1 (en) * 1996-06-28 2002-12-31 Ethicon, Inc. Bioresorbable oxidized cellulose composite material for prevention of postsurgical adhesions
JPH10298435A (ja) * 1997-04-24 1998-11-10 Dainippon Ink & Chem Inc 生分解性成形物、生分解性材料及びそれらの製造方法
GB2354708B (en) * 1999-10-01 2004-06-02 Johnson & Johnson Medical Ltd Compositions for the treatment of wound contracture
JP5963130B2 (ja) * 2012-02-16 2016-08-03 学校法人同志社 生体組織補強材料キット及び生体組織補強材料
JP6006610B2 (ja) * 2012-10-19 2016-10-12 グンゼ株式会社 生体吸収性組織補強材
JP6555125B2 (ja) * 2014-03-31 2019-08-07 東レ株式会社 多層シートおよびそれを用いた一体化シート並びにその製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137402A (zh) * 2004-10-20 2008-03-05 伊西康公司 供医疗装置用的加固可吸收多层织物及其制备方法
CN1799649A (zh) * 2005-12-09 2006-07-12 清华大学 一种血液相容性生物材料及其制备方法
CN102600013A (zh) * 2012-03-21 2012-07-25 苏州博创同康生物工程有限公司 一种医用植绒止血材料及其制备和应用
CN104207879A (zh) * 2013-05-31 2014-12-17 天津法莫西医药科技有限公司 具有羧甲基纤维素钠/聚乳酸海绵保护层的医用敷料

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109937055A (zh) * 2016-11-07 2019-06-25 郡是株式会社 生物组织增强材料和人工硬脑膜
JP2019526305A (ja) * 2016-11-07 2019-09-19 グンゼ株式会社 生体組織補強材料及び人工硬膜
JP2019528806A (ja) * 2016-11-07 2019-10-17 グンゼ株式会社 生体組織補強材料
WO2019071587A1 (fr) * 2017-10-13 2019-04-18 Gunze Limited Kit de matériau de renforcement de tissu biologique et matériau de renforcement de tissu biologique
CN111050812A (zh) * 2017-10-13 2020-04-21 郡是株式会社 生物组织增强材料套件和生物组织增强材料
JP2020526258A (ja) * 2017-10-13 2020-08-31 グンゼ株式会社 生体組織補強材料キット及び生体組織補強材料
CN111050812B (zh) * 2017-10-13 2022-02-25 郡是株式会社 生物组织增强材料套件和生物组织增强材料

Also Published As

Publication number Publication date
JP6470840B2 (ja) 2019-02-13
JP2018513698A (ja) 2018-05-31
CN107530212B (zh) 2021-10-26
CN107530212A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
EP3843796B1 (fr) Pansements composites, leurs procédés de fabrication et leurs applications
CN101897989B (zh) 局部和内部使用的止血剂
EP2156849B1 (fr) Materiau fibreux a base de chitosane, procede de preparation et application associes
RU2686466C2 (ru) Медицинское изделие и способ его изготовления
Hu et al. Assembled anti-adhesion polypropylene mesh with self-fixable and degradable in situ mussel-inspired hydrogel coating for abdominal wall defect repair
EP2792351A1 (fr) Composition antiadhésive, complexe de treillis chirurgical contenant la composition pour fonctions d'anti-adhésion et procédé de fabrication de ceux-ci
JP7537788B2 (ja) 止血被覆材及びその製造方法
JP5963130B2 (ja) 生体組織補強材料キット及び生体組織補強材料
CN106880867A (zh) 一种止血防粘连膜及其制备方法
CN104174065B (zh) 一种可吸收人工血管及其制备方法和应用
WO2016169041A1 (fr) Substance de renforcement de tissus biologiques
CN103418024A (zh) 一种新型可吸收医用材料
WO2017206131A1 (fr) Structure de fibre médicale et stratifié médical
CN109906091B (zh) 生物组织增强材料
Di et al. The utilization of chitosan/Bletilla striata hydrogels to elevate anti-adhesion, anti-inflammatory and pro-angiogenesis properties of polypropylene mesh in abdominal wall repair
JP6678255B2 (ja) 生体組織補強材料及び人工硬膜
CN111050812B (zh) 生物组织增强材料套件和生物组织增强材料
He et al. A super-efficient and biosafe hemostatic cotton gauze with controlled balance of hydrophilicity/hydrophobicity and tissue adhesiveness
JP2023107694A (ja) 消化管吻合部補強材
CN109847111B (zh) 一种包含白及多糖的防粘连材料及其制备方法
CN120227494A (zh) 可吸收组织粘合贴片及其制备方法
CN109395148A (zh) 一种可吸收止血纱
HK1102546B (en) Hemostatic agent for topical and internal use
HK1124268A (zh) 可展开的止血剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15889530

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017533344

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15889530

Country of ref document: EP

Kind code of ref document: A1